Plain-English translation of NCT06837103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →This trial is testing a newer glucose monitoring device called intermittently scanned continuous glucose monitoring (isCGM) to see if it helps people with type 2 diabetes manage their blood sugar more effectively. Some participants will use this monitoring device plus get one consultation with a pharmacist, while others will continue using traditional finger-stick blood glucose testing. The study will measure whether the newer device leads to better blood sugar control over 3 to 6 months.
Many people with type 2 diabetes struggle to keep their blood sugar in a healthy range using traditional testing methods. Researchers want to know if this newer monitoring technology, combined with expert support from a pharmacist, can help patients achieve better control without needing insulin injections.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be placed into one of three groups: one using the new glucose monitoring device with one pharmacist consultation, one using the new device with more extensive coaching support, or one continuing with traditional finger-stick testing. Your participation will last about 3 to 6 months, with a follow-up visit to measure your blood sugar control and see how you're doing. During this time, you'll wear or use the monitoring device as directed and attend your scheduled appointments.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Canada